Prelude Therapeutics Inc. (PRLD): Price and Financial Metrics


Prelude Therapeutics Inc. (PRLD): $35.50

1.57 (+4.63%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

PRLD Stock Price Chart Interactive Chart >

Price chart for PRLD

PRLD Price/Volume Stats

Current price $35.50 52-week high $95.38
Prev. close $33.93 52-week low $23.69
Day low $34.05 Volume 391,800
Day high $36.95 Avg. volume 230,022
50-day MA $33.23 Dividend yield N/A
200-day MA $47.17 Market Cap 1.67B

Prelude Therapeutics Inc. (PRLD) Company Bio


Prelude Therapeutics, Inc. operates as a cancer drug discovery company. It focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Gopi Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.


PRLD Latest News Stream


Event/Time News Detail
Loading, please wait...

PRLD Latest Social Stream


Loading social stream, please wait...

View Full PRLD Social Stream

Latest PRLD News From Around the Web

Below are the latest news stories about Prelude Therapeutics Inc that investors may wish to consider to help them evaluate PRLD as an investment opportunity.

Chief Medical Officer Of Prelude Therapeutics Trades $578.63 Thousand In Company Stock

David Mauro, Chief Medical Officer at Prelude Therapeutics (NASDAQ:PRLD), made a large buy and sell of company shares on September 7, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission reports that on September 7, David Mauro bought 15,000 Prelude Therapeutics shares at a price of $1.89 per share, for a total of $28,350. They then sold their shares on the same day in the open market at prices ranging from $35.91 to $37.79 to raise a tot

Yahoo | September 9, 2021

Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences

WILMINGTON, Del., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in two upcoming virtual investor conferences: Morgan Stanley 19th Annual Global Healthcare ConferenceFireside chat at 11:45 a.m. ET on Thursday, September 9, 2021 H.C. Wainwright 23rd Annual Global Investment ConferenceCorporate presentation at 7:00 a.m. ET on Monday, September 13, 2021 A l

Yahoo | September 2, 2021

Prelude Therapeutics Announces Second Quarter 2021 Financial Results and Operations Update

- Data from Dose Escalation Portion of Phase 1 Trials of Lead Oral PRMT5 Inhibitors PRT543 and PRT811 to be Presented in 4Q21 – - Enrollment Ongoing in Multiple Expansion Cohorts in Phase 1 Trial of PRT543; Dose Expansion Portion of Phase 1 Trial of PRT811 Expected to Commence in 3Q21 – - Dose Escalation Portion of Phase 1 Trials of Oral and IV Formulations of MCL1 Inhibitor PRT1419 Ongoing – -Strong Cash Position of $343 Million to Support Clinical and Discovery Pipeline Advancement – WILMINGTO

Yahoo | August 12, 2021

We're Not Very Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Yahoo | August 11, 2021

Prelude Therapeutics Announces Appointment of Martin Babler to its Board of Directors

WILMINGTON, Del., July 19, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the appointment of Martin Babler to its Board of Directors. Mr. Babler brings to Prelude over 25 years of pharmaceutical and biotech experience, most recently serving as President and Chief Executive Officer of Principia Biopharma until its acquisition by Sanofi S.A. in October 2020. Mr. Babler will serve as a member of the Audit Committee of

Yahoo | July 19, 2021

Read More 'PRLD' Stories Here

PRLD Price Returns

1-mo 11.42%
3-mo 11.29%
6-mo -16.65%
1-year N/A
3-year N/A
5-year N/A
YTD -50.38%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 4.085 seconds.